Diligence memo · auto-generated · as of July 2, 2026
Praetego, Inc.
Praetego, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Praetego, Inc. operates in Pharmaceuticals, based in DURHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Praetego, Inc. has raised $763K in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $413K on 2020-12-24.
Most recent recorded round closed around 2020-12-24.
Valuation (modeled)modeled
Provath models Praetego, Inc. at approximately $15M (range $231K–$144M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.10× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era. Within the normal band (110% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 5.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 16% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Elion Oncology, Inc., Cyclone Therapeutics, Inc., Sonnet Biotherapeutics, Inc., Fastball Capital Group, Llc, TamRx, LLC.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.